BEVERLY, Mass. – The Endicott women's lacrosse team officially announced the newest member of its program on Saturday, March 30 as nine-year-old Ava Beaulieu (Salem, Mass.) joined the Gulls via her Team IMPACT Draft Day, sponsored by Vertex Pharmaceuticals.
Ava's draft day consisted of signing a National Letter of Intent (NLI) during a press conference with local media and accompanying the team to their road game against Gordon College later that day.
"We are very pleased to officially welcome Ava and her family to the Endicott women's lacrosse program," said Endicott women's lacrosse head coach Maureen Spellman. "The team met Ava for the very first time this past weekend and there was an instant connection. Ava already possesses all of the qualities we look for in our athletes, and we are looking forward to getting to know her more. We are very excited to grow in this relationship with Ava and Team IMPACT, and could not be more grateful for the opportunity."
By signing her NLI, Ava will attend Endicott practices, games, team dinners, and events. She also will wear Endicott's colors – blue and green – with tremendous pride, and, most importantly, have fun as a member of the Endicott women's lacrosse program.
Ava is one of 30,000 patients in the United States living courageously with cystic fibrosis (CF), a disease predominantly diagnosed in children by the age of two.
ABOUT TEAM IMPACT
Team IMPACT is a national nonprofit headquartered in Boston that connects children facing serious or chronic illnesses with college athletic teams, forming life-long bonds and life-changing outcomes. Team IMPACT has more than 1,000 teams across the country waiting to be matched with children, ages 5-16, who have been diagnosed with a life-threatening or chronic illness and who could benefit from becoming a member of the team. If you know a child who may be interested, visit www.goteamimpact.org for more information.
ABOUT VERTEX PHARMACEUTICALS
By sponsoring Team IMPACT Draft Days of children with CF, Vertex Pharmaceuticals helps spread awareness for the disease and the lifelong, positive effects Team IMPACT has on children.
Meanwhile, the CF community motivates Vertex employees each day to dig deeper, to do more, to explore the "what ifs," and to push the boundaries of what we know. We aim to discover and develop medicines that will treat the underlying cause of CF for the vast majority of people with the disease, and our ultimate goal is to cure it. Beyond our transformational medicines, we help people with CF lead active lives and pursue higher education, and we fund independent research and innovative patient-centric programs. To learn more please visit www.vrtxallincf.com.
(Photo Credit - Endicott Athletics)